Ep. 253, Chapter 3: Addressing Hepatitis Delta with Mark Eisner, MD

22:12 – 27:22

Hepatitis delta, a rare but severe liver disease that progresses rapidly, requires co-infection with hepatitis B. Hepatitis delta currently has no approved therapies in the U.S., though bulevirtide is used in Europe despite limited efficacy. In partnership with Alnylam Pharmaceuticals, Vir is poised to begin a Phase 3 trial for its combination regimen of tobevibart and elebsiran, which researchers believe can achieve complete viral suppression in most patients. Dr. Eisner emphasizes that partnerships are vital for biopharma companies like Vir to leverage scientific innovation and access global commercialization capabilities.